Merck Sharp + Dohme Corp.

Other

Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

Research Corporation Technologies, Inc.

Teijin Pharma Limited

Merck Sharp & Dohme LLC

Gopalan Raghunathan

David M. Knight

Karen Duffy

Vedrana Stojanovic-Susulic

Theresa J. Goletz

Shizhong Chen

Raymond Sweet

Kristen Picha

Jill M Giles-Komar

David M Knight

Takashi Murakami

Hiroshi H Eguchi

Juan C Almagro

Linda Liang

Laurence Fayadat-Dilman

Rene De Waal Malefyt

Ellen Chi

Alexey Teplyakov

Ronald Swanson

Johan Fransson

Hong Mimi Zhou

Jose R Pardinas

Sheng-Jiun Wu

Jill Carton

Christian Martinez

Glenn Mark Anderson

Karyn O'Neil

Glen A Evans

Linus Hyun

Wolfgang Seghezzi

Raymond W Sweet

Mark Hilary Cunningham

Jeanne E Baker

Drake LaFace

Robert T Sarisky

Lani Rose San Mateo

Yiqing Feng

Carl Mieczkowski

Akira Tanokura

Roberta Lamb

Naoko Namiki

Sophie Parmentier Batteur

William DuBell

Shanrong Zhao

Kam-Fai Tse

Sybil M G Williams

Johann Fransson

Wendy Cordier

Katya McLane

Anuk Das

David Bramhill

Daniel Stephen Malashock

Angela Marie Jablonski

Rene De Malefyt

Mouhamadou L Mbow

Nicole Stowell

Theresa J Goletz

Yiging Feng

Lani San Mateo

Jill Giles-Komar

Mark Cunningham

Sheng-Jium Wu

Juan Carlos Almagro

William Dubell

Juan-Carlos Almagro

Drake Laface

Sybil M Williams

Laurence Fayadat-dilman

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.

Anti-LAG3 antibodies and antigen-binding fragments

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

Anti-TIGIT antibodies

Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

Method of treating osteoarthritis with human oncostatin M antibodies

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAGS as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.

Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies

Polynucleotides encoding human oncostatin M antibodies

Human oncostatin M antibodies

Novel CH2 domain template molecules wherein donor loops from a database of domains are transferred to a CH2 domain scaffold. At least one or up to three loops from a donor are transferred to the CH2 domain. The donor loops may be chosen based on length, e.g., the donor loop may have a length that is similar to that of a structural loop in the CH2 domain scaffold.

CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds

The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.

Human tissue factor antibody and uses thereof

Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a database of human germline genes or human sequences with somatic mutations.

Methods for use in human-adapting monoclonal antibodies

Growing community of inventors

San Diego, CA, United States of America

Gopalan Raghunathan